Signal transduction in EJ-H-ras-transformed cells: De novo synthesis of diacylglycerol and subversion of agonist-stimulated inositol lipid metabolism  by Chiarugi, Vincenzo P. et al.
Volume 252, number 1,2, 129-134 FEB 07448 July 1989 
Signal transduction in EJ-H-ras-transformed cells: de novo 
synthesis of diacylglycerol and subversion of agonist-stimulated 
inositol lipid metabolism 
Vincenzo P. Chiarugi, Lucia Magnelli, Franca Pasquali, Gabriele Basi and Marco Ruggiero 
Laboratory of Molecular Biology, Institute of General Pathology, University of Firenze, Viale Morgagni JO,50134 Firenze, 
Italy 
Received 19 May 1989; revised version received 16 June 1989 
We examined the level of 1,2-diacylglycerol and inositol phosphates in normal and EJ-H-ras-transformed BALB/3T3 
fibroblasts by prelabelling the cells with PHIglycerol, PH]inositol, r*C]gl ucose, PVlarachidonic acid, and P4C]pahnitic 
acid. Steady-state l vel of diacylglycerol was increased in ras-transformed cells prelabelled with radioactive glycerol, glu- 
cose and palmitic acid. Steady-state l vel of inositol phosphates, however, was the same in control and transformed cells. 
Diacylglycerol labelling by PYZ]arachidonic acid was the same in control and transformed cells. Insulin dramatically in- 
creased iacylglycerol labelling by p4C]glucose in normal cells, wheras it did not affect ras-transformed fibroblasts. Neu- 
rotransmitter-induced inositol lipid turnover was greatly enhanced in ras-transformed cells; conversely, platelet-derived 
growth factor and thrombin-stimulated normal cells to a greater extent than transformed fibroblasts. Taken together 
these results suggest that ras transformation may induce multifarious effects on signal transduction: it may cause de novo 
synthesis of diacylglycerol and subversion of neurotransmitter and growth factor receptor coupling to inositol lipid 
metabolism. 
Oncogene, ras; Inositol lipid; Diacylglycerol; Signal transduction 
1. INTRODUCTION 
Since our first observation of altered inositol 
lipid metabolism in rus-transformed cells [l], 
several reports have been published on this con- 
troversial issue [2-191. There seems to be general 
agreement hat ras-transformed cells have increas- 
ed steady-state level of 1 ,Zdiacylglycerol (DAG), 
although discrepancies arise concerning the source 
of this DAG. It has been proposed that DAG 
might derive from constitutive hydrolysis of in- 
ositol lipids [3,12- 151, or other phospholipids 
[6,7,11]; however, these hypotheses have been 
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recently questioned [18,20], and no alternative ex- 
planation for this phenomenon is currently 
available. Another point of controversy concerns 
the responsiveness of ras-transformed cells to a 
number of agents that stimulate inositol lipid 
metabolism [1,2,5,9,10,16-181. Increased or 
decreased responses have been reported and no 
conclusive evidence has been reached so far. 
In this study we approached the problem from a 
different perspective. Based on the old concept 
that transformed cells show increased glucose 
transport and glycolysis, we investigated whether 
DAG was neosynthesized along this pathway. 
Since it has been demonstrated that insulin induces 
de novo synthesis of DAG [21,22], we studied the 
effect of insulin on DAG production in control 
and ras-transformed BALB/3T3 fibroblasts. 
Finally, we reinvestigated the effect of 
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neurotransmitters and growth factors on inositol 
lipid metabolism in ras-transformed cells. Our 
results raise the possibility that ras transformation 
may induce multifaceted alterations in signal 
transduction, influencing DAG neosynthesis and 
the coupling between different receptors and in- 
ositol lipid turnover. 
2. MATERIALS AND METHODS 
myo-[2-3H]Inositol (lo-20 Ci.mmol-I), [2-3H]glycerol 
(1 Ci.mmol-i), D-[U-‘4C]glucose (lo-15 mCi. mmol-I), 
[U-i4C]arachidonic acid (300-1200 mCi.mmol-‘), and 
[U-i4C]palmitic acid (>500 mCi.mmol-‘) were from NEN 
(DuPont). Thin-layer chromatography (TLC) plates (LD6D) 
were from Whatman. Lipid standards were from Sigma. 
Platelet-derived growth factor (PDGF) was from Collaborative 
Research. Thrombin, phenylephrine, carbamylcholine, 
atropine, prazosin, and insulin were from Sigma. All other 
reagents were analytical grade or the best commercially 
available. 
Normal BALB/3T3 and EJ-T24-H-ras-transformed 
fibroblasts were kindly provided by Dr Bignami, Istituto 
Superiore di Sanita, Rome, Italy. This ras cloned cell line con- 
tains about 15 copies of the integrated H-ru.s oncogene. Cell 
cultures were normally grown in 50-mm dishes in DMEM con- 
taining fetal calf serum. It has been observed that DAG and 
phosphoinositide levels in normal and ras-transformed cells are 
affected by conditions of cell density [3]. This observation may 
reflect the fact that normal cells at high density enter a quiescent 
state, whereas transformed cells continue to proliferate [18]. 
Therefore, at the time of each experiment, both normal and 
transformed cell lines were assayed as semiconfluent 
monolayers containing the same number of cells. For ex- 
periments involving measurement of steady-state l vels of DAG 
and inositol phosphates (InsPs), cells were prelabelled to 
equilibrium with different radioisotopes following the method 
described in Lacal et al. [ll]. After radiolabelling, the cultures 
were washed and maintained for only 4 h in serum-free 
medium, after which the medium was removed and cells in- 
cubated for 1 h in serum-free medium. This procedure of short 
serum starvation seems to provide the best experimental condi- 
tions for comparing second messenger levels in normal and ras- 
transformed fibroblasts [1 11. For experiments involving 
measurement of incorporation of different precursors into 
DAG and phosphatidic acid (PA), we followed the procedure 
described by Macara [23] and Peter-Riesch [22]. Also in these 
experiments, cultures were serum starved for 4 h prior to the 
measurements. For experiments designed to measure inositol 
lipid metabolism in response to agonists, cells were prelabelled 
to equilibrium with [‘Hlinositol. Incubation with different 
agents was performed at 37°C for 10 min in the presence of 
LiCl (10 mM). Neurotransmitter eceptor antagonists, when 
present, were added 5 min before the respective agonist. InsPs 
and PA were extracted and separated according to the pro- 
cedure described in Lapetina et al. [24] as modified by Chiarugi 
et al. [25]. DAG was separated by TLC as described in Lacal et 
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Table 1 
Steady-state level of diacylglycerol in control and ras- 
transformed fibroblasts prelabelled with different precursors 
Radioactive precursor BALB/3T3 EJ-H-rus 
[“HIGlycerol 1527 zt 156 4987 f 189 
[‘4C]Glucose 3455 f 107 9888 f 1007 
[14C]Palmitic acid 4567 + 343 10345 + 876 
[“C]Arachidonic acid 2145 + 402 2986 f 78 
Normal and ras-transformed fibroblasts were labelled to 
equilibrium with 0.5 &i/ml of [i4C]glucose, [‘4C]palmitic 
acid, [14C]arachidonic acid, or 2gCVml of [‘HIglycerol for 
48 h. Steady-state level of diacylglycerol was measured 
following the procedure described in LacaI et al. [1 11. Data are 
shown as cpm recovered in diacylglycerol (means f SE, n = 3) 
al. [ll]. All data shown were normalized for the radioactivity 
content in total phospholipids [3,11,25]. 
3. RESULTS 
Table 1 shows that EJ-H-rus-transformed 
BALB/3T3 fibroblasts had increased steady-state 
level of DAG when prelabelled to equilibrium with 
[3H]glycerol, [‘4C]glucose, and [14C]palmitic acid. 
Cells prelabelled with [‘4C]arachidonic acid, 
however, did not show significant increase of DAG 
labelling. This phenomenon was dramatically evi- 
dent under non-equilibrium conditions (fig. 1). 
Labelled DAG and PA were rapidly formed from 
precursors such as [‘4C]glucose, [3H]glycerol and 
[ 14C]palmitic acid in rus-transformed cells; con- 
versely, [14C]arachidonic acid-labelled DAG and 
PA were formed to the same extent in control and 
transformed fibroblasts. These results suggest hat 
DAG may be neosynthesized from the glycolytic 
intermediate dihydroxyacetone phosphate and 
from glycerol 3-phosphate after step-wise acyla- 
tion to 1ysoPA and PA [22]. This hypothesis is sup- 
ported by the observation indicating that DAG and 
PA were preferentially labelled by [r4C]palmitic 
acid rather than [‘4C]arachidonic acid in ras- 
transformants (table 1 and fig.1). As elegantly 
demonstrated by Peter-Riesch et al. [22], palmitic 
acid-rich DAG is formed through a neosynthetic 
pathway, whereas arachidonic acid-rich DAG 
derives from phospholipase C-mediated hydrolysis 
of phospholipids. 
Since it has been reported that insulin increases 
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Fig.1. Incorporation of different labelled precursors into diacylglycerol and phosphatidic acid in control and rus-transformed 
BALB/3T3 fibroblasts. Semiconfluent monolaycrs of normal and EJ-H-rus-transformed BALB/3T3 cells were incubated with 
0.5 &i/ml of [‘4C]glucose, [‘4C]palmitic acid, [‘4C]arachidonic acid, or 2 &i/ml of [“HJglycerol. After addition of each radiolabellcd 
compound, the cells were extracted at different time intervals (minutes, as indicated on the X axis). Time 0 indicates when the 
radiolabelled precursor was added. Extraction and separation of diacylglycerol and phosphatidic acid were performed as described. 
Data are presented as means f SE (n = 3). 
DAG by stimulating de novo PA synthesis [21,22], 
we studied the effect of insulin on the rapid 
kinetics of DAG labelling from [14C]glucose in 
normal cells and rus transformants (fig.2). It is 
clear that insulin did not modify the incorporation 
of glucose-derived 14C into DAG in ras transfor- 
mants, whereas it dramatically increased DAG 
neosynthesis in control fibroblasts. 
We then investigated the responsiveness of ras 
transformants to different receptor agonists in 
terms of InsPs formation. Table 2s hows that ras- 
transformed cells did not exhibit significant 
changes of the basal level of InsPs when assayed in 
the presence of LiCl. These results are in agree- 
ment with previous reports demonstrating an in- 
crease of DAG without a corresponding elevation 
of InsPs [6,7,11]. However, rus transformants 
showed significantly higher responses to the 
muscarinic Ml receptor agonist carbamylcholine, 
and to the al receptor agonist phenylephrine. 
These responses were inhibited by the specific 
receptor antagonists, atropine and prazosin, 
respectively (table 2). PDGF and thrombin, on the 
other hand, efficiently stimulated InsPs formation 
in control BALB/3T3, but failed to induce signifi- 
cant inositol lipid turnover in ru.s transformants. 
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Fig.2. Effect of insulin on the acute transfer of %Z from D- 
[U-“‘Clglucose to diacylglycerol in normal and ras-transformed 
fibroblasts. Experimental conditions were as described in the 
legend to fig.1. Insulin (1 FM) was added together with 
[r4C]glucose at the point indicated as time 0. Results are the 
means of three experiments rt SE (n = 3). 
4. DISCUSSION 
The data presented in this study suggest hat rus- 
transformed cells show complex alterations of 
signal transduction. In particular, we observed 
that ras transformants had elevated steady-state 
level of neosynthesized DAG, and altered coupling 
of growth factor and neurotransmitter receptors to 
inositol lipid metabolism. 
It is well accepted that DAG can be produced in 
response to different agonists through pathways 
Inositol phosphate formation in response to receptor agonists in 
normal and rus-transformed fibroblasts 
Treatment BALB/3T3 EJ-H-ru.s 
None 970 zk 17 1011 f 215 
Carbamylcholine 1207 + 480 4690 f 180 
Atropine + carbamylcholine 1050 f 23 1757 + 150 
Phenylephrine 1075 + 134 3584 k 98 
Prazosin + phenylephrine 1090 + 154 1685 f 78 
Thrombin 2986 f 187 1344 f 41 
PDGF 3160 f 191 1439 f 43 
Cells prelabelled to equilibrium with [‘Hlinositol, were 
incubated with each agonist for 10 min at 37°C in the presence 
of LiCl (10 mM). Inositol phosphates were extracted and 
separated as described [24,25]. Data are presented as cpm 
associated with the total inositol phosphate fraction (means f
SE, n = 3). Carbamylcholine, 10 mM; atropine, 1 mM; 
phenylephrine, 100 pM; prazosin, 100 pM; thrombin, 10 U/ml; 
PDGF, 10 ng/ml 
other than inositol lipid hydrolysis [26,27]. Insulin 
in particular seems to cause de novo synthesis of 
DAG from the glycolytic pathway in different cell 
types [21,22,28]. Insulin and ~21” appear to be 
functionally related: it has been proposed that 
some of the effects of insulin might be mediated by 
~21” [29,30], and it has been demonstrated that 
efficient DNA synthesis by oncogenic p21H-eraS 
only occurs in the presence of insulin [31]. 
Therefore, de novo synthesis of DAG along the 
glycolytic pathway might represent the point of 
convergence of insulin and ~21” action. Consis- 
tent with this idea is the observation that insulin 
can increase DAG neosynthesis in normal cells but 
not in ras transformants (fig.2), as if Tus transfor- 
mants had maximally activated insulin-like 
mechanism(s) for DAG formation. Concerning the 
molecular forms of neosynthesized DAG, at the 
moment it is impossible to demonstrate whether it 
is sn-1,2DAG or sn-2,3DAG. However, since in- 
sulin action and ras transformation have profound 
effects on protein kinase C [6,7,13,19,21,32], it is 
possible that at least some fraction of this neosyn- 
thesized DAG is the sn-1,2DAG. In our opinion, it 
is a racemic mixture of the two forms; however, 
given the significant increase of DAG in ros 
transformants, even if only 50% of this is the 
sn-1,2DAG form, it could be sufficient to explain 
the effects on protein kinase C. 
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Since DAG has been reported to be elevated in 
cell lines transformed by a number of membrane- 
associated oncogene products [4,7,33], it will be in- 
teresting to investigate whether DAG neosynthesis 
is a phenomenon peculiar to ras, or rather com- 
mon to other oncogenes. Given the evidence that 
ras neutralizing antibody Y 13-259 inhibits not only 
ras transformation but blocks transformation by 
SK, fms, and fes, and the mitogenic effects of 
serum, PDGF, EGF and phorbol esters [34-361, it 
is also proposable that ~21” might act as multiple 
coupler between receptors, membrane-associated 
oncogene products and downstream mitogenic 
signalling pathways. However, the picture is 
becoming increasingly intricate since it has been 
demonstrated that ras is able to generate distinct 
signals dependent and independent of functional 
protein kinase C [31]. 
Concerning the effect of ras transformation on 
agonist-induced inositol lipid metabolism, we 
observed that neurotransmitter-induced responses 
were amplified, whereas growth factor-induced ef- 
fects were inhibited (table 2). Altered level of ex- 
pression of different receptors might be 
responsible for this observation. It has been 
demonstrated that fibroblasts transformed by ras 
and other oncogenes show elevated level of 
bradykinin receptors and increased responsiveness 
to the peptide hormone [9,10,37]. However, 
altered inositol lipid turnover in response to car- 
bamylcholine, bombesin, and PDGF in ras- 
transformed cells is not associated with a change in 
receptor number [2,5,9]. An alternative explana- 
tion for these results might be in the different 
coupling of growth factor and neurotransmitter 
receptors to phospholipase C. While neuro- 
transmitter receptors are generally coupled via G- 
proteins [38], recent data suggest hat growth fac- 
tor receptors directly phosphorylate and activate 
the enzyme [39]. Therefore ~21” might substitute 
for G-proteins coupling neurotransmitter receptors 
to inositol lipid metabolism, whereas persistent ac- 
tivation of protein kinase C elicited by elevated 
DAG might impair growth factor-dependent 
signalling. Further studies are required to deter- 
mine the importance of these alterations of signal 
transduction in malignant transformation. 
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